Welcome to our dedicated page for XOMA Corporation news (Ticker: $XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XOMA Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XOMA Corporation's position in the market.
Rhea-AI Summary
XOMA Corporation acquires economic interest in DSUVIA® from Talphera, Inc. for $8 million, with a 15% royalty on commercial sales and a significant portion of the 75% royalty from U.S. Department of Defense purchases. XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments. DSUVIA® received Milestone C approval from the U.S. Department of Defense for use in U.S. Army sets, kits, and outfits (SKOs) and was added to the DoD Joint Deployment Formulary in September 2020. XOMA will receive 100% of all royalties and milestones related to DSUVIA® sales until the Company receives $20 million, after which XOMA fully retains the 15% royalty associated with DSUVIA® commercial sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
-
Rhea-AI Summary
XOMA Corporation (NASDAQ: XOMA) announced that the FDA has accepted Zevra Therapeutics' New Drug Application for arimoclomol, a first-in-class therapy for Niemann-Pick disease type C (NPC), with a PDUFA target action date of June 21, 2024. XOMA will make a $1 million milestone payment to LadRx based on the FDA's acceptance. The company previously paid LadRx a $5 million upfront payment and acquired a mid-single digit royalty on arimoclomol's commercial sales, with potential milestone payments of up to $52.6 million, net, from Zevra. The transaction also included a royalty rate on commercial sales of aldoxorubicin and potential payments of up to $343 million in development and commercial milestones from ImmunityBio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
-
Rhea-AI Summary
XOMA Corporation (XOMA) announced the appointment of Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Hughes has been serving as XOMA's Executive Chairman and Interim CEO since January 1, 2023. The Board aims to establish XOMA as a premier biotech royalty aggregator, focusing on accelerating growth and maximizing value for stockholders. The company's growing cash receipts and maturing portfolio reflect significant inflection points within its established royalty and milestone acquisition strategy. XOMA also boasts the largest cash balance in its history.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announces its first stock repurchase program, authorizing the purchase of up to $50 million of common stock through January 2027. The company aims to maximize shareholder value through prudent capital allocation, leveraging future cashflow streams of its growing royalty portfolio to generate superior risk-adjusted, non-correlated returns for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.92%
Tags
-
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a cash dividend of $0.53906 per share, while holders of depositary shares for XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive a cash dividend of $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) secures $140 million non-dilutive, non-recourse, royalty-backed loan from Blue Owl Capital Inc. (NYSE: OWL) to fund stock repurchases and additional royalty and milestone acquisitions. The loan is repayable over a 15-year period at a fixed interest rate of 9.875% per year, with the option to draw an additional $10 million based on VABYSMO® (faricimab) sales. XOMA has also issued warrants to purchase up to 120,000 shares of its common stock to Blue Owl at implied premiums of 122%, 170%, and 217% to the closing stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
Rhea-AI Summary
XOMA Corporation reported $6.6 million in cash receipts, a NDA filing, and anticipated Phase 3 program initiation, with third-quarter 2023 revenues of $0.8 million and G&A expenses of $6.4 million. The company received a $4.9 million cash payment from Roche and earned a $5 million milestone related to the FDA's acceptance of Day One Biopharmaceuticals' NDA for tovorafenib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
-
Rhea-AI Summary
XOMA Corporation announces earning a $5 million milestone for the FDA acceptance of Day One Biopharmaceuticals' New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted Priority Review and set a PDUFA date of April 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
-
Rhea-AI Summary
XOMA Corporation announces cash dividends for Series A and Series B Cumulative Preferred Stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
Rhea-AI Summary
XOMA Corporation to present company update at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
XOMA Corporation
Nasdaq:XOMAO
XOMAO Rankings
XOMAO Stock Data
7.95M
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
EMERYVILLE
About XOMAO
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.